A5067072628- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Single-cell and spatial transcriptomics
- Cancer, Lipids, and Metabolism
- T-cell and B-cell Immunology
- Sarcoma Diagnosis and Treatment
- RNA modifications and cancer
- Molecular Biology Techniques and Applications
- Renal and related cancers
- Vascular Tumors and Angiosarcomas
- CAR-T cell therapy research
Memorial Sloan Kettering Cancer Center
2021-2024
Kettering University
2024
Abstract The most prominent homozygous deletions in cancer affect chromosome 9p21.3 and eliminate CDKN2A/B tumor suppressors, disabling a cell-intrinsic barrier to tumorigenesis. Half of deletions, however, also encompass type I interferon (IFN) gene cluster; the consequences this co-deletion remain unexplored. To functionally dissect other large genomic we developed flexible deletion engineering strategy, MACHETE (molecular alteration chromosomes with engineered tandem elements). Applying...
Abstract Despite recent advancements in lung adenocarcinoma (LUAD) treatment, mortality remains high. Thus, a need exists for novel therapeutic concepts to enhance treatment efficacy and improve patient survival. Cancer cell plasticity, the capacity cancer cells differentiate adapt cell-extrinsic pressures, drives LUAD progression enables resistance. We discovered molecularly distinct "high-plasticity state" (HPCS), which emerges during initial stages of tumor development is maintained...
Abstract S2 Genomics developed the Singulator™ 100 and 200 Systems to automate processing of fresh, frozen, or OCT tissues into single cell nuclei suspensions using disposable cartridges, reagents, customizable protocols. The systems have been used prepare cells from a wide range organisms, including human, mouse, chicken, insects, snails, zebrafish, plants. Formalin-fixed, paraffin-embedded (FFPE) are preferred format for pathologists as many one billion FFPE slides in repositories. tissue...
SUMMARY Somatic chromosomal deletions are prevalent in cancer, yet their functional contributions remain ill-defined. Among the most prominent of these events chromosome 9p21.3, which disable a cell intrinsic barrier to tumorigenesis by eliminating CDKN2A/B tumor suppressor genes. However, half 9p21.3 encompass cluster 16 type I interferons (IFNs) whose co-deletions have not been functionally characterized. To dissect how and other genomic impact we developed MACHETE (Molecular Alteration...